US FDA Approves Emergency Use Authorization For Convalescent Plasma
Two days after holding its verdict on authorizing convalescent plasma as emergency use for COVID-19, the US Food and Drugs Administration approved the therapy for emergency use on Sunday.
The FDA believes that this therapy may be effective in treating COVID-19 and that the known and potential benefits of the product outweigh the known and potential risks of the product.
The Commissioner, Dr.Steven Hahn in his address stated that studies witnessed a 35% improvement in survival with this therapy which is a substantial clinical benefit.
"A 35 percent improvement in survival is a pretty substantial clinical benefit," FDA Commissioner @SteveFDA said in relation to the convalescent plasma emergency use authorization issued today. pic.twitter.com/Dd97vLSZeL
— U.S. FDA (@US_FDA) August 23, 2020